Amarna Therapeutics, a Leiden, the Netherlands-based biotechnology company, raised €10m in funding.
The round was led by Flerie Invest AB with an innovation credit coming from the “Netherlands Enterprise Agency” (RVO.nl) and existing shareholder Pim Berger.
The company plans to use this funding to progress development of its SVac platform towards a first-in-man clinical study to commence in two to three years from now.
Founded in 2008 and led by Ben van Leent, CEO, Amarna Therapeutics is a biotech company that is developing a next-generation SV40-based gene delivery vector platform named SVac that aims to transform gene-replacement and immunotherapy across many disease areas including genetic disorders, degenerative/inflammatory/autoimmune diseases, infectious diseases and cancer.
The company, which also has a research facility in Seville, Spain, has genetically engineered the SV40 genome used for the production of vector particles and in parallel generated a novel Vero-based packaging cell line named SuperVero that produces similar numbers of vector particles to the currently used packaging cell lines but without contaminating wild type SV40 particles.